{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:30:19Z","timestamp":1787311819321,"version":"build-2736575974"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.7759\/cureus.114914","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:47:00Z","timestamp":1787309220000},"source":"Crossref","is-referenced-by-count":0,"title":["Reducing Daytime Sedation While Preserving Motor Function in Parkinson\u2019s Disease Psychosis: A Case Report of Psychotropic Timing and Deprescribing"],"prefix":"10.7759","author":[{"given":"Garrison","family":"Burky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0600-5","article-title":"Psychosis in Parkinson\u2019s disease: epidemiology, pathophysiology, and management","volume":"76","author":"Chang A","year":"2016","unstructured":"Chang A, Fox SH. Psychosis in Parkinson\u2019s disease: epidemiology, pathophysiology, and management. Drugs. 2016, 76:1093-118. 10.1007\/s40265-016-0600-5","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00330-6","article-title":"The neuropsychiatry of Parkinson's disease: advances and challenges","volume":"21","author":"Weintraub D","year":"2022","unstructured":"Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, Schrag A. The neuropsychiatry of Parkinson's disease: advances and challenges. Lancet Neurol. 2022, 21:89-102. 10.1016\/S1474-4422(21)00330-6","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong MJ","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020, 323:548-60. 10.1001\/jama.2019.22360","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings J","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, et al.. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014, 383:533-40. 10.1016\/S0140-6736(13)62106-6","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson's disease","volume":"403","author":"Foltynie T","year":"2024","unstructured":"Foltynie T, Bruno V, Fox S, Kuhn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson's disease. Lancet. 2024, 403:305-24. 10.1016\/S0140-6736(23)01429-0","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott IA","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, et al.. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015, 175:827-34. 10.1001\/jamainternmed.2015.0324","journal-title":"JAMA Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00577-7","article-title":"Circadian rhythms in neurodegenerative disorders","volume":"18","author":"Nassan M","year":"2022","unstructured":"Nassan M, Videnovic A. Circadian rhythms in neurodegenerative disorders. Nat Rev Neurol. 2022, 18:7-24. 10.1038\/s41582-021-00577-7","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30461-7","article-title":"Association between circadian rhythms and neurodegenerative diseases","volume":"18","author":"Leng Y","year":"2019","unstructured":"Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol. 2019, 18:307-18. 10.1016\/S1474-4422(18)30461-7","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","unstructured":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023, 71:2052-81. 10.1111\/jgs.18372","journal-title":"J Am Geriatr Soc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526021-reducing-daytime-sedation-while-preserving-motor-function-in-parkinsons-disease-psychosis-a-case-report-of-psychotropic-timing-and-deprescribing","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:47:02Z","timestamp":1787309222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526021-reducing-daytime-sedation-while-preserving-motor-function-in-parkinsons-disease-psychosis-a-case-report-of-psychotropic-timing-and-deprescribing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.114914","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}